Our Commitment

  • Lorus recognizes the urgency in addressing the need for safe and effective cancer therapies, and is committed to advancing our drug pipeline expeditiously to bring our products to market and thereby enhance the quality of life of cancer patients.
  • This commitment to science and quality of life is entirely consistent with our commitment to our shareholders. We believe that our focus on effective and well-tolerated drug products that can be used alone or in combination with other cancer regimes has the best potential to increase shareholder value.

Lorus is a clinical stage cancer drug development company with a strong commitment to discovering, developing and commercializing innovative molecular targeted therapies addressing major unmet medical needs. Our drug pipeline addresses novel and validated cancer targets using RNA-targeted, Small Molecule and Immunotherapy technologies with high safety profiles.